| Not Yet Recruiting | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Y NCT07440290 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy NCT07222800 | Pfizer | Phase 3 |
| Recruiting | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 NCT05770544 | Cancer Research UK | Phase 2 / Phase 3 |
| Active Not Recruiting | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations NCT07038369 | Atavistik Bio, Inc | Phase 1 |
| Recruiting | Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 NCT06785636 | Pathos AI, Inc. | Phase 1 / Phase 2 |
| Recruiting | 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prost NCT06706921 | VA Greater Los Angeles Healthcare System | Phase 4 |
| Active Not Recruiting | Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study NCT06494241 | AstraZeneca | — |
| Recruiting | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations NCT06988475 | Cancer Research UK | Phase 2 / Phase 3 |
| Active Not Recruiting | Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC NCT06376084 | AstraZeneca | — |
| Recruiting | Early Intervention Strategies for Lung Cancer NCT06988943 | The First Affiliated Hospital of Guangzhou Medical University | N/A |
| Recruiting | Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab NCT06237920 | The Netherlands Cancer Institute | Phase 2 |
| Recruiting | Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal C NCT06365866 | Taipei Veterans General Hospital, Taiwan | N/A |
| Recruiting | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Pos NCT05770037 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-S NCT06177925 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Recruiting | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Canc NCT05770102 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | Real World Registry for Use of the Ion Endoluminal System NCT06004440 | Intuitive Surgical | — |
| Terminated | Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 NCT05980416 | Elevation Oncology | Phase 1 |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748 | NiKang Therapeutics, Inc. | Phase 2 |
| Completed | Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiat NCT05895994 | MEI HENG | EARLY_Phase 1 |
| Completed | CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL NCT05716113 | He Huang | EARLY_Phase 1 |
| Recruiting | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Part NCT05592626 | Marengo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer NCT05386108 | Stemline Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patient NCT05252078 | Jiangxi Provincial Cancer Hospital | Phase 2 |
| Unknown | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRP NCT05150236 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 |
| Recruiting | OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry. NCT04493632 | OncoSil Medical Limited | — |
| Terminated | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873 | Blueprint Medicines Corporation | Phase 1 |
| Terminated | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408 | Blueprint Medicines Corporation | Phase 1 |
| Completed | Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands Duri NCT05022667 | University of Michigan | N/A |
| Recruiting | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors a NCT04572451 | Yana Najjar | Phase 1 |
| Active Not Recruiting | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cance NCT04807166 | Wenjun Cheng | Phase 2 |
| Terminated | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780 | Blueprint Medicines Corporation | Phase 1 |
| Terminated | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic NCT04644315 | Hoffmann-La Roche | Phase 2 |
| Recruiting | Spanish Series of Patients Treated With the Radionuclide Lutetium177 NCT04949282 | Sociedad Española de Medicina Nuclear e Imagen Molecular | — |
| Completed | High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy NCT04461509 | Alessandro D'Agnolo | Phase 2 |
| Withdrawn | The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients NCT03003195 | University of Arkansas | Phase 2 |
| Unknown | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patien NCT04697446 | Blueprint Medicines Corporation | — |
| Completed | Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial NCT04679675 | Kaiser Permanente | N/A |
| Unknown | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian NCT04556071 | Xiaoxiang Chen | Phase 2 |
| Unknown | Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Un NCT05322486 | State Scientific Centre of Coloproctology, Russian Federation | — |
| Unknown | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer NCT04566952 | Xiaoxiang Chen | Phase 2 |
| Active Not Recruiting | Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gas NCT05602935 | The Second Affiliated Hospital of Fujian Medical University | Phase 2 |
| Terminated | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer NCT04222972 | Hoffmann-La Roche | Phase 3 |
| Terminated | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRP NCT04249947 | Poseida Therapeutics, Inc. | Phase 1 |
| Completed | Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients NCT04080843 | Zhejiang University | Phase 2 |
| Recruiting | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preve NCT04061967 | Karolinska Institutet | N/A |
| Active Not Recruiting | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma NCT04124198 | Christian von Buchwald | N/A |
| Completed | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) NCT03656718 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Promoting Physical Activity in Young Adult Cancer Survivors Using mHealth and Adaptive Tailored Feedback Strat NCT03569605 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Savolitinib vs. Sunitinib in MET-driven PRCC. NCT03091192 | AstraZeneca | Phase 3 |
| Completed | A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC NCT03134872 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | International Lung Screen Trial (ILST) NCT02871856 | The University of Queensland | N/A |
| Completed | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Unknown | uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer NCT02960724 | Rigshospitalet, Denmark | Phase 2 |
| Completed | Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen NCT05113134 | Seoul National University Bundang Hospital | N/A |
| Active Not Recruiting | A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Inj NCT02266745 | Promontory Therapeutics Inc. | Phase 2 |
| Completed | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic NCT01964430 | Celgene | Phase 3 |
| Terminated | A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy NCT02111824 | The Methodist Hospital Research Institute | Phase 1 |
| Completed | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 Wit NCT01968109 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Unknown | Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC NCT01917279 | Binghe Xu | Phase 3 |
| Unknown | Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous In NCT01995942 | Royal Marsden NHS Foundation Trust | — |
| Terminated | Protection of Rectum From High Radiation Doses Using a Spacer NCT01918605 | University of Oulu | N/A |
| Completed | Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors NCT01629758 | Bristol-Myers Squibb | Phase 1 |
| Completed | A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma NCT01576380 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate He NCT01556815 | Shandong Cancer Hospital and Institute | Phase 2 |
| Completed | ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Ca NCT01472146 | Susanne Crocamo | Phase 2 |
| Unknown | The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction NCT01427400 | University of British Columbia | Phase 4 |
| Terminated | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) NCT01009593 | Abbott | Phase 3 |
| Unknown | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks NCT01037049 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Completed | Guarana (Paullinia Cupana) for Breast Cancer Chemotherapy-related Fatigue NCT01043913 | Faculdade de Medicina do ABC | Phase 2 |
| Completed | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients NCT00562224 | Pharmacyclics LLC. | Phase 1 |
| Unknown | Low Rectal Cancer Study (MERCURY II) NCT02005965 | Royal Marsden NHS Foundation Trust | — |
| Completed | A Trial for Patients With Advanced/Recurrent Endometrial Cancer NCT00377520 | Eli Lilly and Company | Phase 2 |
| Completed | Studying Normal Breast Tissue and Cancer Risk NCT00341692 | National Cancer Institute (NCI) | — |
| Completed | A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer NCT00050427 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |
| Completed | A Study of Trabectedin in Patients With Advanced Ovarian Cancer NCT00050414 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |
| Terminated | Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for NCT00384891 | Medical Enterprises Europe B.V. | Phase 3 |
| No Longer Available | Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC NCT06841874 | Nuvation Bio Inc. | — |
| Withdrawn | SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolut NCT02254915 | Medical Enterprises Europe B.V. | Phase 3 |